Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APR-246 and Azacitidine in TP53 Mutant Myeloid Neoplasms
NCT03588078Phase 2Completed
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Sep 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eprenetapopt in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), Myeloproliferative Neoplasm (MPN), chronic myelomonocytic leukemia (CMML), sponsored by Groupe Français des Myélodysplasies. Started Sep 2018; status: completed.
02
Drugs
eprenetapopt
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)Myeloproliferative Neoplasm (MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT03588078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03588078.